These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

280 related items for PubMed ID: 6356902

  • 21. Monotherapy with labetalol compared with propranolol. Differential effects by race.
    Flamenbaum W, Weber MA, McMahon FG, Materson BJ, Carr AA, Poland M.
    J Clin Hypertens; 1985 Mar; 1(1):56-69. PubMed ID: 3915317
    [Abstract] [Full Text] [Related]

  • 22. Labetalol in essential hypertension.
    Larochelle P, Hamet P, Hoffman B, Kuchel O, McKenzie J, Mitenko P, Ogilvie RI, Ruedy J.
    J Cardiovasc Pharmacol; 1980 Mar; 2(6):751-9. PubMed ID: 6160325
    [Abstract] [Full Text] [Related]

  • 23. Labetalol, a cross-over double blind controlled trial.
    Sanders GL, Routledge PA, Rao JG, Gales GM, Davies DM, Rawlins MD.
    Eur J Clin Pharmacol; 1978 Dec 18; 14(5):301-4. PubMed ID: 365543
    [Abstract] [Full Text] [Related]

  • 24. Labetalol blunts morning pressor surge in systolic hypertension.
    DeQuattro V, Lee DD, Allen J, Sirgo M, Plachetka J.
    Hypertension; 1988 Feb 18; 11(2 Pt 2):I198-201. PubMed ID: 3278976
    [Abstract] [Full Text] [Related]

  • 25. Double-blind study of dilevalol and captopril, both in combination with hydrochlorothiazide, in patients with moderate to severe hypertension.
    McGrath BP, Matthews PG, Louis W, Howes L, Whitworth JA, Kincaid-Smith PS, Fraser I, Scheinkestel C, MacDonald G, Rallings M.
    J Cardiovasc Pharmacol; 1990 Nov 18; 16(5):831-8. PubMed ID: 1703608
    [Abstract] [Full Text] [Related]

  • 26. Study of single and multiple dose pharmacokinetic/pharmacodynamic modeling of the antihypertensive effects of labetalol.
    Maronde RF, Robinson D, Vlachakis ND, Barr JW, Chung M, Zampaglione N, Medakovic M.
    Am J Med; 1983 Oct 17; 75(4A):40-6. PubMed ID: 6356898
    [Abstract] [Full Text] [Related]

  • 27. Isradipine vs propranolol in hydrochlorothiazide-treated hypertensives. A multicenter evaluation.
    Prisant LM, Carr AA, Nelson EB, Winer N, Velasquez MT, Gonasun LM.
    Arch Intern Med; 1989 Nov 17; 149(11):2453-7. PubMed ID: 2530945
    [Abstract] [Full Text] [Related]

  • 28. Treatment of isolated systolic hypertension with labetalol in the elderly.
    Giles TD, Weber M, Bartels DW, Silberman HM, Gilderman LP, Burris JF.
    Arch Intern Med; 1990 May 17; 150(5):974-6. PubMed ID: 2184794
    [Abstract] [Full Text] [Related]

  • 29. A multicenter double-blind study of the efficacy and safety of once and twice daily dilevalol compared to propranolol.
    Schoenberger JA, Wallin JD, Gorwit JI, Davidov ME, Michelson EL, Poland MP, Frishman WH.
    Am J Hypertens; 1989 Nov 17; 2(11 Pt 1):840-6. PubMed ID: 2686711
    [Abstract] [Full Text] [Related]

  • 30. Experience with labetalol in essential hypertension.
    Tuomilehto J, Nissinen A, Elo J.
    Curr Med Res Opin; 1980 Nov 17; 6(6):407-15. PubMed ID: 7363641
    [Abstract] [Full Text] [Related]

  • 31. Comparison of labetalol, hydrallazine, and propranolol in the therapy of moderate hypertension.
    West MJ, Wing LM, Mulligan J, Walkley J, Grygiel JJ, Graham JR, Chalmers JP.
    Med J Aust; 1980 Mar 08; 1(5):224-5. PubMed ID: 6990215
    [Abstract] [Full Text] [Related]

  • 32. Tiapamil and hydrochlorothiazide: a double-blind comparison of two antihypertensive agents.
    Storm TL, Badskjaer J, Hammer R, Kögler P.
    J Clin Pharmacol; 1987 Jan 08; 27(1):18-21. PubMed ID: 3316301
    [Abstract] [Full Text] [Related]

  • 33. Effects of labetalol and propranolol on the peripheral circulation in hypertensive patients.
    Nyberg G, Berglund G.
    Acta Med Scand Suppl; 1982 Jan 08; 665():93-101. PubMed ID: 6961763
    [Abstract] [Full Text] [Related]

  • 34. Controlled comparison of labetalol and propranolol in the management of severe hypertension.
    Pugsley DJ, Armstrong BK, Nassim MA, Beilin LJ.
    Br J Clin Pharmacol; 1976 Aug 08; 3(4 Suppl 3):777-82. PubMed ID: 791331
    [Abstract] [Full Text] [Related]

  • 35. Labetalol in the treatment of essential hypertension: a single-blind dose ranging study.
    Dux S, Grosskopf I, Boner G, Rosenfeld JB.
    J Clin Pharmacol; 1986 Aug 08; 26(5):346-50. PubMed ID: 3700690
    [Abstract] [Full Text] [Related]

  • 36. Multicenter comparison of dilevalol to placebo in patients with mild hypertension.
    Frishman WH, Schoenberger JA, Gorwit JI, Bedsole GD, Cubbon J, Poland MP.
    Am J Hypertens; 1988 Jul 08; 1(3 Pt 3):295S-299S. PubMed ID: 3046631
    [Abstract] [Full Text] [Related]

  • 37. Labetalol in resistant hypertension.
    Hedstrand H.
    Acta Med Scand Suppl; 1982 Jul 08; 665():125-8. PubMed ID: 6961758
    [Abstract] [Full Text] [Related]

  • 38. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM, Malacco E, Khder Y, Kandra A, Bönner G, Heintz D.
    Clin Ther; 2005 May 08; 27(5):578-87. PubMed ID: 15978306
    [Abstract] [Full Text] [Related]

  • 39. A comparison of the effects of labetalol, bendrofluazide and their combination in hypertension.
    Dawson A, Johnson BF, Smith IK, Munro-Faure AD.
    Br J Clin Pharmacol; 1979 Aug 08; 8(2):149-54. PubMed ID: 385023
    [Abstract] [Full Text] [Related]

  • 40. Combined alpha- and beta-adrenoceptor blockade with labetalol in hypertension.
    Frick MH, Pörsti P.
    Br Med J; 1976 May 01; 1(6017):1046-8. PubMed ID: 773498
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.